OVARIAN CANCER and US: low grade serous ovarian

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label low grade serous ovarian. Show all posts
Showing posts with label low grade serous ovarian. Show all posts

Monday, April 30, 2012

Endometriosis and ovarian cancer – Authors' reply : The Lancet Oncology



Endometriosis and ovarian cancer – Authors' reply : The Lancet Oncology


"Both Vercellini and colleagues and Guo and colleagues raise concerns about screening, with which we agree. Our findings should not suggest to clinicians or the public that screening for ovarian cancer should be implemented for women with endometriosis. Rather, we hope that our work stimulates further research that can refine risk groups related to endometriosis on the basis of anatomical site, epidemiological risk factors, or molecular features. Vercellini and colleagues raise an interesting point about atypical endometriosis, but this diagnosis is not standardised or commonly used and can not be addressed in epidemiological studies.
..................Regardless, the attenuated associations remain statistically significant.

(another) commentary: Endometriosis and ovarian cancer : The Lancet Oncology



Endometriosis and ovarian cancer : The Lancet Oncology

correspondence: Endometriosis and ovarian cancer : The Lancet Oncology



Endometriosis and ovarian cancer : The Lancet Oncology

Wednesday, April 04, 2012

Phase 2 Study Update of Selumetinib for Ovarian Cancer - MPR



Blogger's Note: more info req'd eg. side effects....

Phase 2 Study Update of Selumetinib for Ovarian Cancer - MPR

Array BioPharma announced results of a Phase 2 trial of selumetinib in women with recurrent low-grade serous ovarian or peritoneal cancer.

In the trial, 52 women each received 100mg doses of selumetinib orally twice daily in four-week cycles until disease progression or toxicity. The median number of cycles received was 4.5; 33% underwent ≥12 cycles. Prior to the trial, 58% of the patients in the trial had received three or more rounds of chemotherapy.

A disease control rate, defined as either complete or partial response or progression-free survival or progression-free survival of greater than 6 months, occurred in 81% of patients. Eight patients had complete (1) or partial (7) responses, and 34 (63%) had progression-free survival of >6 months. The median survival rate without cancer progression was 11 months.

Selumetinib is an anti-cancer drug in Phase 2 development in a range of tumors. It is a small molecule MEK inhibitor that targets a key position in the Ras-Raf-MEK-ERK signaling pathway. MEK has been shown to be frequently activated in cancer, in particular in tumors that have mutations in the RAS and RAF pathways.

For more information call (877) MED-CHEM or visit www.arraybiopharma.com